File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Angiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES)

TitleAngiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES)
Authors
KeywordsCardiotonic Agents/*administration & dosage
*Coronary Angiography
Coronary Restenosis/epidemiology
Coronary Stenosis/radiography/*therapy
*Drug-Eluting Stents
Female
Humans
Male
Middle Aged
Myocardial Infarction/epidemiology
Sirolimus/administration & dosage/*analogs & derivatives
Issue Date2013
Citation
Journal of Interventional Cardiology, 2013, v. 26 n. 1, p. 22-28 How to Cite?
AbstractOBJECTIVES: The purpose of this study was to examine the angiographic and clinical results of stent full metal jacket in treating long lesions using everolimus-eluting stents (EES). BACKGROUND: Data are lacking regarding the use of EES for this lesion subgroup. METHODS: From 2007 to 2011, 77 symptomatic patients who had severe coronary stenoses necessitating implantation of stents with total length longer than 60 mm were treated with overlapping EES. RESULTS: The mean age of patient was 61 +/- 11 years with male predominance (66%). Diabetes mellitus was seen in 35 (45.5%) patients. Majority of patients had class III angina with normal heart function. On average, 3.1 stents were implanted per lesion; the mean stent size and length were 2.70 +/- 0.28 mm and 82 +/- 16 mm. Restudy angiography was performed on 71 patients (72 lesions) at 8.9 +/- 2.5 months. Angiographic restenosis was seen in 9 (12.5%) lesions; the lesion length and late loss were 67 +/- 15 mm and 0.4 +/- 0.6 mm, respectively. The use of intravascular ultrasound has been found to be a predictor of less restenosis (P = 0.02; HR: 0.02; CI: 0.01-0.59). The in-hospital and 1 year major adverse cardiac event rates were 7.8% and 13%. The annual cardiac death rates were 2.6%, 3.4%, and 5.3% in the first 3 years. CONCLUSIONS: The use of EES full metal jacket for long lesions is only associated with good short-term clinical and angiographic outcomes. Long-term follow-up has revealed a high cardiac death rate which may necessitate prolongation of dual antiplatelet therapy.
Persistent Identifierhttp://hdl.handle.net/10722/207693
ISSN
2015 Impact Factor: 1.327
2015 SCImago Journal Rankings: 0.787

 

DC FieldValueLanguage
dc.contributor.authorJim, MHen_US
dc.contributor.authorYiu, KHen_US
dc.contributor.authorHo, HHen_US
dc.contributor.authorChan, WLen_US
dc.contributor.authorNg, AKen_US
dc.contributor.authorSiu, DCWen_US
dc.contributor.authorChow, WHen_US
dc.date.accessioned2015-01-19T04:20:05Z-
dc.date.available2015-01-19T04:20:05Z-
dc.date.issued2013en_US
dc.identifier.citationJournal of Interventional Cardiology, 2013, v. 26 n. 1, p. 22-28en_US
dc.identifier.issn0896-4327en_US
dc.identifier.urihttp://hdl.handle.net/10722/207693-
dc.description.abstractOBJECTIVES: The purpose of this study was to examine the angiographic and clinical results of stent full metal jacket in treating long lesions using everolimus-eluting stents (EES). BACKGROUND: Data are lacking regarding the use of EES for this lesion subgroup. METHODS: From 2007 to 2011, 77 symptomatic patients who had severe coronary stenoses necessitating implantation of stents with total length longer than 60 mm were treated with overlapping EES. RESULTS: The mean age of patient was 61 +/- 11 years with male predominance (66%). Diabetes mellitus was seen in 35 (45.5%) patients. Majority of patients had class III angina with normal heart function. On average, 3.1 stents were implanted per lesion; the mean stent size and length were 2.70 +/- 0.28 mm and 82 +/- 16 mm. Restudy angiography was performed on 71 patients (72 lesions) at 8.9 +/- 2.5 months. Angiographic restenosis was seen in 9 (12.5%) lesions; the lesion length and late loss were 67 +/- 15 mm and 0.4 +/- 0.6 mm, respectively. The use of intravascular ultrasound has been found to be a predictor of less restenosis (P = 0.02; HR: 0.02; CI: 0.01-0.59). The in-hospital and 1 year major adverse cardiac event rates were 7.8% and 13%. The annual cardiac death rates were 2.6%, 3.4%, and 5.3% in the first 3 years. CONCLUSIONS: The use of EES full metal jacket for long lesions is only associated with good short-term clinical and angiographic outcomes. Long-term follow-up has revealed a high cardiac death rate which may necessitate prolongation of dual antiplatelet therapy.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Interventional Cardiologyen_US
dc.subjectCardiotonic Agents/*administration & dosageen_US
dc.subject*Coronary Angiographyen_US
dc.subjectCoronary Restenosis/epidemiologyen_US
dc.subjectCoronary Stenosis/radiography/*therapyen_US
dc.subject*Drug-Eluting Stentsen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectMyocardial Infarction/epidemiologyen_US
dc.subjectSirolimus/administration & dosage/*analogs & derivativesen_US
dc.titleAngiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES)en_US
dc.typeArticleen_US
dc.identifier.emailYiu, KH: khkyiu@hku.hken_US
dc.identifier.authorityYiu, KH=rp01490en_US
dc.identifier.doi10.1111/joic.12006en_US
dc.identifier.hkuros254869-
dc.identifier.volume26en_US
dc.identifier.issue1en_US
dc.identifier.spage22en_US
dc.identifier.epage28en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats